All In Biotech

Free tool

FAERS Monitor: Semglee

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761201 or its brand name (Semglee, Insulin Glargine-Yfgn). Reports on generic versions are filed under their own applications.

Reports

22,377

Serious

19,546

87% of reports

Hospitalization

11,755

Death reported

2,448

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hypoglycaemia1,741
  • blood glucose increased1,627
  • acute kidney injury1,066
  • dyspnoea1,005
  • nausea971
  • off label use957
  • hyperglycaemia952
  • drug ineffective923
  • diarrhoea919
  • vomiting856
  • fatigue828
  • condition aggravated768
  • fall688
  • dizziness681
  • asthenia676

Reports by year received

View as table
YearReports
200499
2005108
200689
2007111
2008169
2009191
2010299
2011360
2012263
2013403
2014420
2015617
2016722
2017877
20182,418
20192,583
20201,570
20211,584
20221,964
20231,844
20242,236
20251,721
20261,728

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,031,782 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypoglycaemiaSignal1,74135.033.455,463
hyperglycaemiaSignal95225.223.721,550
blood glucose increasedSignal1,6278.27.810,248
acute kidney injurySignal1,0666.66.25,047
condition aggravatedSignal7682.42.2619
fall6881.91.8319
vomiting8561.71.6258
asthenia6761.71.6193
dyspnoea1,0051.71.6276
diarrhoea9191.31.381
dizziness6811.31.243
nausea9711.21.120
off label use9571.01.01
fatigue8281.00.90
drug ineffective9230.70.6174

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.